Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal of translational autoimmunity·2026
Same author

Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Machine learning, whole genome sequencing, and Mendelian randomization support a role of CRP on COVID-19 severity.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026

Related Experiment Video

Updated: May 21, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

N-TproBNP as biomarker in systemic sclerosis.

Tommaso Schioppo1, Carolina Artusi, Teresa Ciavarella

  • 1Chair and Division of Rheumatology, Department of Internal Medicine, Istituto G. Pini, University of Milan & IRCCS Istituto Auxologico Italiano, Milan, Italy.

Clinical Reviews in Allergy & Immunology
|June 7, 2012
PubMed
Summary

N-terminal pro-brain natriuretic peptide (N-TproBNP) shows promise for diagnosing pulmonary arterial hypertension in systemic sclerosis (SSc). Further research is needed to clarify its role in SSc-related lung fibrosis and skin conditions.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Experiment Videos

Last Updated: May 21, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Area of Science:

  • Rheumatology
  • Cardiology
  • Pulmonology

Background:

  • Systemic sclerosis (SSc) is a severe autoimmune disease causing fibrosis and vasculopathy, often leading to poor prognosis.
  • Early detection of organ involvement is crucial for effective treatment in SSc patients.
  • Current biomarkers for SSc lack accuracy in predicting organ-specific manifestations and disease activity.

Purpose of the Study:

  • To review the role of N-terminal pro-brain natriuretic peptide (N-TproBNP) as a biomarker in systemic sclerosis.
  • To assess the utility of N-TproBNP in predicting cardiac, pulmonary, and skin involvement in SSc.
  • To present findings from a recent study on N-TproBNP in an SSc patient cohort.

Main Methods:

  • Extensive literature review of studies investigating N-TproBNP in SSc.
  • Analysis of existing data on N-TproBNP's association with SSc manifestations.
  • Presentation of results from a cohort study of 87 SSc patients.

Main Results:

  • N-TproBNP is a validated biomarker for diagnosing and predicting pulmonary arterial hypertension in SSc.
  • Evidence suggests N-TproBNP's utility in cardiac assessment for SSc patients.
  • The role of N-TproBNP as a biomarker for pulmonary fibrosis and skin involvement in SSc remains unclear.

Conclusions:

  • N-TproBNP is a significant biomarker for pulmonary arterial hypertension and cardiac assessment in systemic sclerosis.
  • Further investigation is required to establish N-TproBNP's role in predicting pulmonary fibrosis and skin manifestations of SSc.
  • N-TproBNP holds potential for improving SSc patient management through early risk stratification.